JP7796008B2 - 抗ｃｄ３７１抗体およびその使用 - Google Patents

抗ｃｄ３７１抗体およびその使用

Info

Publication number
JP7796008B2
JP7796008B2 JP2022516402A JP2022516402A JP7796008B2 JP 7796008 B2 JP7796008 B2 JP 7796008B2 JP 2022516402 A JP2022516402 A JP 2022516402A JP 2022516402 A JP2022516402 A JP 2022516402A JP 7796008 B2 JP7796008 B2 JP 7796008B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547718A (ja
JP2022547718A5 (https=
JPWO2021050857A5 (https=
Inventor
アンソニー ダニヤン，
レニアー ジェイ． ブレントジェンズ，
イボ シー． ロレンツ，
メアリー アン ポール，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
トライ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート， インコーポレイテッド
スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ
メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, トライ－インスティテューショナル セラピューティクス ディスカバリー インスティテュート， インコーポレイテッド, スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ, メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2022547718A publication Critical patent/JP2022547718A/ja
Publication of JP2022547718A5 publication Critical patent/JP2022547718A5/ja
Publication of JPWO2021050857A5 publication Critical patent/JPWO2021050857A5/ja
Priority to JP2025135892A priority Critical patent/JP2025183231A/ja
Application granted granted Critical
Publication of JP7796008B2 publication Critical patent/JP7796008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022516402A 2019-09-13 2020-09-11 抗ｃｄ３７１抗体およびその使用 Active JP7796008B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135892A JP2025183231A (ja) 2019-09-13 2025-08-18 抗ｃｄ３７１抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900118P 2019-09-13 2019-09-13
US62/900,118 2019-09-13
US201962936913P 2019-11-18 2019-11-18
US62/936,913 2019-11-18
PCT/US2020/050380 WO2021050857A1 (en) 2019-09-13 2020-09-11 Anti-cd371 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135892A Division JP2025183231A (ja) 2019-09-13 2025-08-18 抗ｃｄ３７１抗体およびその使用

Publications (4)

Publication Number Publication Date
JP2022547718A JP2022547718A (ja) 2022-11-15
JP2022547718A5 JP2022547718A5 (https=) 2025-02-06
JPWO2021050857A5 JPWO2021050857A5 (https=) 2025-02-06
JP7796008B2 true JP7796008B2 (ja) 2026-01-08

Family

ID=74866534

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516402A Active JP7796008B2 (ja) 2019-09-13 2020-09-11 抗ｃｄ３７１抗体およびその使用
JP2025135892A Pending JP2025183231A (ja) 2019-09-13 2025-08-18 抗ｃｄ３７１抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135892A Pending JP2025183231A (ja) 2019-09-13 2025-08-18 抗ｃｄ３７１抗体およびその使用

Country Status (11)

Country Link
US (1) US20220195064A1 (https=)
EP (1) EP4028422A4 (https=)
JP (2) JP7796008B2 (https=)
KR (1) KR20220069961A (https=)
CN (1) CN114641503B (https=)
AU (1) AU2020346886A1 (https=)
BR (1) BR112022004603A2 (https=)
CA (1) CA3154387A1 (https=)
IL (1) IL291280A (https=)
MX (1) MX2022003074A (https=)
WO (1) WO2021050857A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002392A1 (en) * 2021-07-20 2023-01-26 Abl Bio Inc. Anti-cll-1/anti-cd3 bispecific antibodies and uses thereof
EP4584283A1 (en) 2022-11-14 2025-07-16 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
WO2025193609A1 (en) 2024-03-11 2025-09-18 Caribou Biosciences, Inc. Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519336A (ja) 2012-05-07 2015-07-09 セレラント セラピューティクス インコーポレイテッド Ｃｌｌ−１に対して特異的な抗体
WO2017091615A1 (en) 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Humanized anti-cll-1 antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543635A (en) * 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
ES2650224T3 (es) * 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP3453723B1 (en) * 2012-01-31 2021-08-11 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
WO2016069549A1 (en) * 2014-10-28 2016-05-06 Albert Einstein College Of Medicine, Inc. Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins
WO2015174978A1 (en) * 2014-05-15 2015-11-19 R-Pharm Overseas, Inc. Antibodies against human receptor integrin alpha-4
EP3221351B1 (en) * 2014-11-19 2024-11-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
SI3115376T1 (sl) * 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
RU2019121662A (ru) * 2016-12-16 2021-01-18 Мерк Патент Гмбх Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита
CA3154389A1 (en) * 2019-09-13 2021-03-18 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting cd371 and uses thereof
KR20240087985A (ko) * 2022-12-13 2024-06-20 엘지디스플레이 주식회사 표시장치

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519336A (ja) 2012-05-07 2015-07-09 セレラント セラピューティクス インコーポレイテッド Ｃｌｌ−１に対して特異的な抗体
WO2017091615A1 (en) 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Humanized anti-cll-1 antibodies

Also Published As

Publication number Publication date
CA3154387A1 (en) 2021-03-18
JP2022547718A (ja) 2022-11-15
US20220195064A1 (en) 2022-06-23
IL291280A (en) 2022-05-01
CN114641503A (zh) 2022-06-17
MX2022003074A (es) 2022-06-14
JP2025183231A (ja) 2025-12-16
WO2021050857A8 (en) 2021-05-27
AU2020346886A1 (en) 2022-04-14
CN114641503B (zh) 2025-10-17
WO2021050857A1 (en) 2021-03-18
BR112022004603A2 (pt) 2022-08-02
EP4028422A4 (en) 2024-01-10
KR20220069961A (ko) 2022-05-27
EP4028422A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
US11725059B2 (en) Antibodies targeting B-cell maturation antigen and methods of use
US20240076370A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
US10913796B2 (en) Antibodies targeting Fc receptor-like 5 and methods of use
JP7796008B2 (ja) 抗ｃｄ３７１抗体およびその使用
EA049349B1 (ru) Антитела против cd371 и их применение
HK40058700A (en) Antibodies targeting b-cell maturation antigen and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251222

R150 Certificate of patent or registration of utility model

Ref document number: 7796008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150